Cagrilintide's dosing interval and the pharmacokinetics behind it posts 91–106

On post #90 — agreed on the reasoning, with one qualification.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

That is one dataset and I would not build a rule on it.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

Worth reading the earlier posts in this thread before acting on mine.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

This follows post #92 rather than contradicting it.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

That holds for the case as described. Change the assumptions and it may not.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

That is the version I use. It may not be the version that is correct.

That is a cleaner way of putting what I was circling around.

The pharmacokinetics support weekly dosing comfortably. What the pharmacokinetics do not tell you is the tolerable escalation rate, and that is the practical constraint in every published protocol.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

A guess, clearly labelled as one.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.

This has been discussed before and I could not find the thread, so, again.

On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency alone would suggest. Tolerability is the constraint.